Last updated on September 2018

Hepatocellular Carcinoma Study Comparing Vaccinia Virus Based Immunotherapy Plus Sorafenib vs Sorafenib Alone

Brief description of study

This is a randomized Phase 3 study to determine whether treatment with vaccinia virus based immunotherapy (Pexa-Vec) followed by sorafenib increases survival compared to treatment with sorafenib in patients with advanced hepatocellular carcinoma who have not received prior systemic therapy.

Detailed Study Description

This is a multi-center, randomized, open-label, Phase 3 study comparing Pexa Vec followed by sorafenib versus sorafenib in patients with advanced HCC without prior systemic therapy.

A total of 600 patients will be randomly assigned to 2 treatment arms in a 1:1 ratio (300 in each arm) to reach at least 570 evaluable patients.

Clinical Study Identifier: NCT02562755

Contact Investigators or Research Sites near you

Start Over

Stephanie Fairbairn

Site No. 8414
Heidelberg, Australia
  Connect »

Stephanie Fairbairn

Site No. 8408
Fitzroy, Australia
  Connect »

Stephanie Fairbairn

Site No. 8402
Parkville, Australia
  Connect »

Stephanie Fairbairn

Site No. 8411
Melbourne, Australia
  Connect »

Stephanie Fairbairn

Site No. 8405
Footscray, Australia
  Connect »